Top Markets
#1 龙虾 (Lobster) 龙虾 (Lobster) +111.56%
#2 Lisk Lisk +79.88%
#3 Not in Employment, Education, or Training Not in Employment, Education, or Training +32.86%
#4 Tokenlon Tokenlon +28.91%
#5 Nockchain Nockchain +28.07%
#6 Alchemist AI Alchemist AI +25.95%
#7 earnAUSD earnAUSD +24.75%
#8 Illuvium Illuvium +22.65%
#9 Renzo Renzo +21.31%
#10 Akedo Akedo +18.08%
Coin of the day
龙虾 (Lobster) 龙虾 (Lobster)
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
MultiCell Technologies, Inc. MultiCell Technologies, Inc.

MultiCell Technologies, Inc.

MCET
Rang in Aktien #41009
MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm,... MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm, primarily focused on the creation of innovative therapeutic agents and research tools. Their efforts are directed towards addressing a range of medical challenges, including neurological conditions, liver ailments, various types of cancer, and applications within interventional cardiology and peripheral vascular health. The company's product pipeline features several key developments: MCT-125: This investigational therapy is currently in Phase II clinical trials, targeting the primary fatigue commonly associated with multiple sclerosis. MCT-465: A preclinical-stage synthetic double-stranded RNA (dsRNA) candidate, designed to act as a powerful immune enhancer for the treatment of solid tumor malignancies. MCT-485: Another dsRNA therapeutic, still in the discovery phase, which demonstrates tumor cytolytic (cell-destroying) properties, intended for use against diverse cancers. Beyond drug candidates, MultiCell Technologies is also progressing the Ideal BioStent, an innovative bioabsorbable stent specifically engineered for use in interventional cardiology and peripheral vessel procedures. The organization maintains licensing agreements with prominent entities such as Corning Incorporated and Pfizer Inc. Established in 1962, the company was previously known as Exten Industries, Inc. before officially changing its name to MultiCell Technologies, Inc. in April 2004. Its corporate headquarters are situated in Woonsocket, Rhode Island.
Aktienkurs
$0.00001
Zuletzt synchronisiert: 2026-09-10
Marktkapitalisierung
$50.01K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel MultiCell Technologies, Inc. (MCET)

Kategorie

Healthcare
Gewinn für MultiCell Technologies, Inc. (MCET)
Gewinn im Aug 2015 TTM: $-253.70
Laut den aktuellen Finanzberichten von MultiCell Technologies, Inc. betragen die aktuellen Gewinne des Unternehmens $-253.70. Im Jahr 2013 erzielte das Unternehmen einen Gewinn von $-1.37K, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von MultiCell Technologies, Inc. von 2013 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
2026 (TTM) $-253.70 -52.03%
2014 $-528.83 -61.38%
2013 $-1.37K 0.00%
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -2,079,155,336.02%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -768,868,584.14%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 1,216,772,201.58%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 1,583,024,389.96%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH